RT Conference Proceedings
T1 Efficacy and safety evaluation of nilotinib and dasatinib (2G -TKI) on first line treatment in 73 patients with CML-CP outside of clinical trials. Andalusian CML registry (RALMC)
A1 Puerta, JM
A1 Jiménez Velasco, A
A1 García, MJ
A1 Molina, JR
A1 Ruiz, C
A1 Ferrer, C
A1 Durán, MS
A1 Simón, I
A1 Clavero, E
A1 Avellaneda, MC
A1 Rosell, A
A1 Ballesteros, I
A1 Ramírez, S
A1 Portero, MA
A1 Ramírez, MJ
A1 Fernández, M
A1 Jiménez, M
A1 Fe, R
A1 Mulero, N
A1 López, P
K1 Dasatinib
K1 Humanos
K1 Mesilato de imatinib
K1 Leucemia mielogenosa crónica BCR-ABL positiva
K1 Pirimidinas
K1 Sistema de registros
K1 Andalucía
AB Even though they were approved last June 2011 to be used on first line, it is not a common procedure to begin treatment of CML-CP with 2GTKI, despite it has been demonstrated its efficacy and safety against imatinibon ENESTnd and Dasision clinical trials.
PB Ferrata Storti Foundation
SN 0390-6078
YR 2016
FD 2016-06
LK http://hdl.handle.net/10668/2445
UL http://hdl.handle.net/10668/2445
LA en
NO Puerta JM, Jiménez Velasco A, García MJ, Molina JR, Ruiz C, Ferrer C, et al.Efficacy and safety evaluation of nilotinib and dasatinib (2G -TKI) on first line treatment in 73 patients with CML-CP outside of clinical trials. Andalusian CML registry (RALMC). Haematologica. 2016; 101(s1).PB1820
DS RISalud
RD Mar 18, 2025